^
    Back
    Association details:
    Biomarker:BCR-ABL1 F359C
    Cancer:Chronic Myeloid Leukemia
    Drug:Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    In particular, V299L, T315A and F317L/V/I/C are resistant to dasatinib. Y253H, E255K/V and F359V/C/I are resistant to nilotinib, and V299L to bosutinib.
    DOI:
    10.1093/annonc/mdx219
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Treatment recommendations based on BCR-ABL1 mutation profile...The table below lists the BCR-ABL1 mutations that should not be treated with bosutinib, dasatinib or nilotinib in the second-line setting...Nilotinib…T315I, Y253H, E255K/V, or F359V/C/I or G250E
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

    Excerpt:
    Patients with mutations that were less sensitive to nilotinib in vitro (IC(50) > 150 nM; Y253H, E255V/K, F359V/C) had less favorable responses, as 13%, 43%, and 9% of patients with each of these mutations, respectively, achieved MCyR; none achieved CCyR. The most common mutations associated with progression were the E255K/V, F359C/V, Y253H, and T315I mutations.
    DOI:
    10.1200/JCO.2009.21.8230